ClinicalTrials.gg
CompletedNCT02395055Updated Nov 5, 2021Results posted

Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

A Phase 1 interventional study of Adalimumab (BCD-057) and Adalimumab (Humira) in Healthy, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Biocad · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety and tolerability profile of BCD-057 (adalimumab biosimilar candidate manufactured by CJSC BIOCAD, Russia) and Humira when used as a single subcutaneous injection in healthy volunteers.

Read the detailed description

This is single center comparative double blind randomized clinical study of pharmacokinetics, tolerance and safety of single subcutaneous injection of BCD-057 (CJSC BIOCAD, Russia) and Humira in healthy volunteers. The purpose of the study is to demonstrate that BCD-057 is equivalent to Humira in terms of pharmacokinetics, tolerability and safety after single subcutaneous injection in healthy volunteers.

The study will enroll 94 healthy volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive BCD-057; volunteers from the second group will receive Humira. Both study and reference drug will be used at the standard dose of 40 mg.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subject has provided ;
  • male gender;
  • 18 - 45 years of age inclusively;
  • a (BMI) between 18,5 and 30 kg/m2;
  • absence of hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality at screening or/and in anamnesis;
  • parameters of complete blood count, blood biochemistry and urinalysis do not exceed reference values, which are used at Study site laboratory. Evaluation of required laboratory parameters must be performed within 14 days before randomization;
  • normal hemodynamic parameters: systolic BP 100 - 139 mm Hg, diastolic BP - 60 - 90 mm Hg, heart rate - 60 - 90 b/min;
  • results are normal for this age group;
  • absence of chronic infections (, syphilis, hepatitis В or С) and chronic inflammation;
  • absence of active or latent tuberculosis;
  • absence of infections within 4 weeks before randomization;
  • absence of mental disorders or other conditions, which may affect the ability of participant to follow Protocol;
  • health well-being (by volunteer's opinion) for at least 30 days before randomization;
  • ability to follow Protocol procedures;
  • consent of volunteers and their sexual partners with to use adequate during screening period and the main study part;
  • absence of alcohol or drug addiction signs (incl. history of such addiction);
  • consent not to consume alcohol within 24 hours before SC injection of BCD-057/Humira and not to use more than 10 units of alcohol per week during the study (1 alcohol unit is equal ½ l of beer (1 pint), or 200 ml of wine, or 50 ml alcohol)

Exclusion criteria

Exclusion Criteria:

  • history of adalimumab use or any other TNF inhibitors;
  • known severe allergy (anaphylaxis or multidrug intolerance);
  • known intolerance of monoclonal antibodies or any other of BCD-057/Humira;
  • major surgery within 30 days before ICF signing;
  • presence of hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality at screening or/and in anamnesis.
  • infections which required hospitalization, parenteral anti-infectives within 6 months before randomization;
  • positive results of tests for -1 and HIV-2 antibodies, positive Hbs-Ag, HBc IgM, total antibodies against , positive results of RPR-test;
  • more than 4 episodes of acute respiratory infection within 6 months before randomization;
  • any (present or history);
  • tuberculosis, including latent forms;
  • shingles (present or history).
  • history of seizures;
  • any disorders or other conditions, which may affect pharmacokinetics of BCD-057/Humira (e.g. chronic liver diseases, chronic kidney diseases, cardiovascular disorders, lung disorders, endocrine diseases, etc.).
  • use of systemic antimicrobial or antifungal medicines within 2 months before randomization;
  • regular oral or parenteral use of any medicines, vitamins, biologically active additives within two weeks before signing of ICF;
  • any use of medicines, vitamins, biologically active additives within 30 days before signing of ICF;
  • use of medicines, which may influence on immunity within 30 days before signing of ICF;
  • vaccination within 4 weeks prior randomization;
  • smoking of more than 10 cigarettes per day;
  • use of alcohol, which exceeds 10 units per week (1 alcohol unit is equal ½ l of beer (1 pint), or 200 ml of vine, or 50 ml alcohol). History of alcohol or drug addiction;
  • donation of more than 450 ml of blood or plasma within 2 months prior randomization;
  • simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation;
  • previous participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    BCD-057 group

    BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.

    Drug: Adalimumab (BCD-057)

  • Active comparator
    Humira group

    Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.

    Drug: Adalimumab (Humira)

Interventions

  • Adalimumab is a monoclonal antibody against tumor necrosis factor alpha

    Also known as: BCD-057, Humira, Trudexa

  • Adalimumab is a monoclonal antibody against tumor necrosis factor alpha

    Also known as: Trudexa

06

What researchers measure

Primary outcomes

  1. Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  2. Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  2. Time to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  3. Half-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira

    Time frame: 0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  4. Volume of Distribution of Adalimumab After Single Administration of BCD-057/Humira

    Time frame: 0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  5. Clearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

  6. Elimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira

    Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose

07

Results

Posted May 23, 2016

Participant flow

Participant flow — Overall Study
MilestoneBCD-057 GroupHumira Group
Started4747
Completed4044
Not completed73
Withdrew: Withdrawal by subject73

Outcome measures

PrimaryMaximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · ng/ml
Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira
ng/mlBCD-057 GroupHumira Group
Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira4426 (3524 to 5902)4522 (3546 to 5104)
PrimaryArea Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · (ng/ml)*hour
Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity
(ng/ml)*hourBCD-057 GroupHumira Group
Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity2488188 (1809194 to 2827564)2272029 (1815831 to 2904679)
SecondaryArea Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · (ng/ml)*hour
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.
(ng/ml)*hourBCD-057 GroupHumira Group
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.2488187 (1809193 to 2778993)2272029 (1815831 to 2858812)
SecondaryTime to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · hours
Time to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
hoursBCD-057 GroupHumira Group
Time to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira120 (96 to 192)108 (90 to 150)
SecondaryHalf-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame:
0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · hours
Half-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
hoursBCD-057 GroupHumira Group
Half-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira263.35 (194.65 to 351.61)269.68 (196.29 to 317.01)
SecondaryVolume of Distribution of Adalimumab After Single Administration of BCD-057/Humira
Time frame:
0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · ml/kg
Volume of Distribution of Adalimumab After Single Administration of BCD-057/Humira
ml/kgBCD-057 GroupHumira Group
Volume of Distribution of Adalimumab After Single Administration of BCD-057/Humira7165.85 (5105.07 to 8482.38)6622.06 (5637.07 to 7854.49)
SecondaryClearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · ml/(h*kg)
Clearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira
ml/(h*kg)BCD-057 GroupHumira Group
Clearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira16.08 (14.39 to 22.11)17.61 (13.99 to 22.04)
SecondaryElimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame:
0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Reported as:
Median · fraction of drug eliminated per hour
Elimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
fraction of drug eliminated per hourBCD-057 GroupHumira Group
Elimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira0.003 (0.002 to 0.004)0.003 (0.002 to 0.004)

Adverse events

Collected over 70 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-057 Group—0/40 (0%)9/40 (22.5%)
Humira Group—0/44 (0%)14/44 (31.8%)
Most frequent other events
Most frequent other events
EventBCD-057 GroupHumira Group
Elevated ALTHepatobiliary disorders3/4011/44
Elevated ASTHepatobiliary disorders3/403/44
NeutropeniaBlood and lymphatic system disorders2/401/44
MonocytosisBlood and lymphatic system disorders2/400/44
MonocytopeniaBlood and lymphatic system disorders2/401/44
HyperbilirubinemiaHepatobiliary disorders2/402/44
LeucopeniaBlood and lymphatic system disorders1/402/44

Baseline characteristics

Population for all type of analysis included 84 patients who received at least one study drug injection.

Age, Categorical
Age, Categorical(Participants)BCD-057 GroupHumira GroupTotal
<=18 years000
Between 18 and 65 years404484
>=65 years000
Age, Continuous
Age, Continuous(years)BCD-057 GroupHumira GroupTotal
Median24.5 (22 to 30.5)25.5 (22 to 29)25 (22 to 30)
Sex: Female, Male
Sex: Female, Male(Participants)BCD-057 GroupHumira GroupTotal
Female000
Male404484
08

Study locations

1 site
  • LLC BioEk
    Saint-Petersburg, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2015
First posted
Mar 20, 2015
Start
Jun 2015
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
May 23, 2016
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02395055
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Jun 2015
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
May 23, 2016
Last update
Nov 5, 2021

Study contacts

Roman Ivanov, Phd
study chair · CJCS BIOCAD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion